ACXP: Acurx Pharmaceuticals Inc. Company Short-Term Debt

Acurx Pharmaceuticals (ACXP) develops innovative antibiotics for the treatment of resistant infections, providing the company with exceptional pricing power. Its competitive advantage is based on patents that protect intestinal microflora while eliminating pathogens. Experienced management effectively minimizes FDA risks, with the indicator standing at 0.00. The current stock quotes displayed on the GURU.Markets chart confirm the market status of this biotech project.

Short-term debts measure the volume of financial obligations with a maturity horizon of up to one year, allowing for an assessment of current liquidity and default risk. An analysis of total short-term liabilities demonstrates a steady reduction in debt, which is critically important for Acurx Pharmaceuticals (ACXP), as fixed costs for clinical trials require strict capital control until the company achieves monopoly profits following FDA approval.